

*陳益程醫師

所有發表期刊論文

1. Liaw YF*, **Chen YC**, Sheen IS. Spontaneous clearance of hepatitis B surface antigen in chronic hepatitis B virus infection confers a favorable response. *Hepatology* 1999;29:296-297.
2. **Chen YC**, Chien RN*, Chen MF, Ng KF, Tseng JH. Biliary hamartomas associated with biliary stones presenting as multiple microabscesses: case report. *Chang Gung Medical Journal* 2000;23:560-565.
3. **Chen YC**, Sheen IS, Chu CM, Liaw YF*. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. *Gastroenterology* 2002;123:1084-1089.
4. **Chen YC**, Yeh TS, Tseng JH, Huang SF, Lin DY*. Hepatic hydatid cysts with superinfection in a non-endemic area in Taiwan. *Am J Trop Med Hyg* 2002;67:524-527.
5. **Chen YC***, Yeh CN, Tseng JH. Symptomatic adult annular pancreas. *J Clin Gastroenterol* 2003;36:446-450.
6. Liaw YF*, **Chen YC**, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. *Gastroenterology* 2004;126:1024-1029.
7. Lin SM*, Lin CJ, Lin CC, Hsu CW, **Chen YC**. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma \leq 4 cm. *Gastroenterology* 2004;127:1714-1723.
8. Lin SM*, Lin CJ, Lin CC, Hsu CW, **Chen YC**. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. *Gut* 2005;54:1151-1156.
9. Yeh CT*, Hsu CW, Chang ML, Sheen IS, Lin SM, Lin CJ, Lin CC, **Chen YC**, Chen JC. A novel ex vivo assay of interferon-based suppression, to predict the outcome of antiviral therapy for hepatitis C. *J Infect Dis* 2006;193:1365-70.
10. **Chen YC**, Chu CM, Yeh CT, Liaw YF*. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. *Hepatol Int* 2007;1:267-273.
11. Sheen IS*, Tsou YK, Lin SM, Lin CJ, Lin CC, Hsu CW, **Chen YC**, Chang ML, Yeh CT. Nuclear HBcAg and histology activity index as independent predictors of the expression of singly spliced HBV-RNA. *J Viral Hepatitis* 2007;14:70-74.
12. Lin CY*, Tsai MC, Huang CT, Hsu CW, Tseng SC, Tsai IF, **Chen YC**, Yeh CT, Sheen IS, Chien RN. Liver injury is associated with enhanced regulatory T-cell

activity in patients with chronic hepatitis B. *J Viral Hepatitis* 2007;14:503-511.

13. Lin SM*, Lin CC, Chen WT, **Chen YC**, Hsu CW. Radiofrequency Ablation for Hepatocellular Carcinoma: A Prospective Comparison of Four Radiofrequency Devices. *J Vasc Interv Radiol* 2007;18:1118-1125.
14. Cua IH, Lin CC, Lin CJ, Chen WT, Hsu CW, **Chen YC**, Wong SN, Lin SM*. Treatment of hepatocellular carcinoma using internally cooled electrodes. A prospective comparison of modified automated vs. manual pulsed radiofrequency algorithms. *Oncology* 2007;72 Suppl 1:76-82.
15. Chen WT, Lin SM*, Lin CJ, Lin CC, Hsu CW, **Chen YC**. Pneumoperitoneum following percutaneous radiofrequency ablation of hepatocellular carcinoma unrelated to bowel injury: a case report. *Hepato-Gastroenterol* 2007;54:2365-2367.
16. Lin CC, Lin CJ, Hsu CW, **Chen YC**, Chen WT, Lin SM*. Fine-needle aspiration cytology to distinguish dysplasia from hepatocellular carcinoma with different grades. *J Gastroen Hepatol* 2008;23:e146-52.
17. Yeh CT*, Tang JH, Hsu CW, **Chen YC**, Chang ML, Lin CY. Expression of hepatitis B virus nuclear core antigen in young cirrhotic patients is associated with an unfavourable long-term outcome. *J Viral Hepatitis* 2008;15:839-848.
18. Yeh CT*, Hsu CW, **Chen YC**, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. *J Clin Virol* 2009;45:114-8.
19. **Chen YC**, Chu CM, Liaw YF*. Age-specific prognosis following HBeAg seroconversion in chronic hepatitis B. *Hepatology* 2010;51:435-444.
20. Chu CM*, **Chen YC**, Tai DI, Liaw YF. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. *Clin Gastroenterol Hepatol* 2010; 8:535-40.
21. Yeh CT*, Chen T, Hsu CW, **Chen YC**, Lai MW, Liang KH, Chen TC. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. *BMC Cancer* 2011; 11:398-407.
22. **Chen YC**, Huang SF, Chu CM, Liaw YF*. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. *J Viral Hepatitis* 2012;19:138-146.
23. **Chen YC**, Jeng WJ, Chu CM, Liaw YF*. Decreasing levels of hepatitis B surface antigen predict hepatitis B surface antigen seroclearance in patients with inactive chronic hepatitis B virus infection. *Clin Gastroenterol Hepatol* 2012;10:297-302.

24. Hsu CW*, Chao YC, Lee CM, Chang TT, **Chen YC**. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24. *BMC Gastroenterology* 2012, 12:178-185.
25. Chan HL*, **Chen YC**, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. *J Viral Hepatitis* 2012;19:732-743.
26. Chu CM*, Lin CC, **Chen YC**, Jeng WJ, Lin SM, Liaw YF. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. *British Journal of cancer* 2012;107:2010-2015.
27. **Chen YC***. Hepatitis B Surface Antigen (HBsAg) Levels in the Prediction of Spontaneous HBsAg Seroclearance. *Hepatology* 2013;57:1675.
28. **Chen YC***, Liaw YF. The Role of HBsAg Quantification in the Natural Course of HBV Infection in Asia. *Curr Hepatitis Rep* 2013;12:174-180.
29. Jeng WJ, Sheen IS, **Chen YC**, Hsu CW, Chien RN, Chu CM, Liaw YF*. Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients. *Hepatology* 2013; 58:1888-1896.
30. **Chen YC**, Hsu CW, Chang MY, Yeh CT*. On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study. *BMC Research Notes* 2013;6:349.
31. Liang KH, **Chen YC**, Hsu CW, Chang ML, Yeh CT*. Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glomerular filtration rates. *Hepat Mon* 2014;14:e15074.